Mingyu Pharmaceutical's Hong Kong IPO Application Lapses After Six Months

Stock News

May 26

Mingyu Pharmaceutical Co., Ltd. (referred to as Mingyu Pharmaceutical) has seen its Hong Kong stock exchange listing application lapse. The application, submitted on November 24, 2025, reached the end of its six-month validity period on May 24, 2026. At the time of submission, Morgan Stanley, BofA Securities, and CITIC Securities were acting as its joint sponsors.

According to the prospectus, Mingyu Pharmaceutical, founded in 2018, is a biotechnology innovation company. The company operates with a dual growth strategy: a robust clinical-stage oncology portfolio built upon its proprietary antibody-drug conjugate (ADC) platform and a novel PD-1/VEGF bispecific antibody (bsAb), alongside its own late-stage immunology assets advancing towards commercialization.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1105006085"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1105006085\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1105006085?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-26 11:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105006085","market":"us","top_or_hot":-1,"title":"Mingyu Pharmaceutical's Hong Kong IPO Application Lapses After Six Months","media":"Stock News","content":"<p>Mingyu Pharmaceutical Co., Ltd. (referred to as Mingyu Pharmaceutical) has seen its Hong Kong stock exchange listing application lapse. The application, submitted on November 24, 2025, reached the end of its six-month validity period on May 24, 2026. At the time of submission, Morgan Stanley, BofA Securities, and CITIC Securities were acting as its joint sponsors.</p>\n<p>According to the prospectus, Mingyu Pharmaceutical, founded in 2018, is a biotechnology innovation company. The company operates with a dual growth strategy: a robust clinical-stage oncology portfolio built upon its proprietary antibody-drug conjugate (ADC) platform and a novel PD-1/VEGF bispecific antibody (bsAb), alongside its own late-stage immunology assets advancing towards commercialization.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mingyu Pharmaceutical's Hong Kong IPO Application Lapses After Six Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMingyu Pharmaceutical's Hong Kong IPO Application Lapses After Six Months\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-26 11:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Mingyu Pharmaceutical Co., Ltd. (referred to as Mingyu Pharmaceutical) has seen its Hong Kong stock exchange listing application lapse. The application, submitted on November 24, 2025, reached the end of its six-month validity period on May 24, 2026. At the time of submission, Morgan Stanley, BofA Securities, and CITIC Securities were acting as its joint sponsors.</p>\n<p>According to the prospectus, Mingyu Pharmaceutical, founded in 2018, is a biotechnology innovation company. The company operates with a dual growth strategy: a robust clinical-stage oncology portfolio built upon its proprietary antibody-drug conjugate (ADC) platform and a novel PD-1/VEGF bispecific antibody (bsAb), alongside its own late-stage immunology assets advancing towards commercialization.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01477","symbol_name":"欧康维视生物-B","start_time":0,"source_url":"","article_id":"1105006085","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105006085","pubTimestamp":1779764902,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Mingyu Pharmaceutical Co., Ltd. (referred to as Mingyu Pharmaceutical) has seen its Hong Kong stock exchange listing application lapse. The application, submitted on November 24, 2025, reached the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01477":"欧康维视生物-B","SPCX":"SPAC and New Issue ETF","IPOS":"Renaissance International IPO ETF","VXUS":"国际股票ETF-Vanguard","BK4588":"碎股","BK1191":"制药","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股"},"translate_title":"明宇药业香港IPO申请半年后失效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPOS":1,"VXUS":1,"01477":1,"SPCX":1},"content_text":"Mingyu Pharmaceutical Co., Ltd. (referred to as Mingyu Pharmaceutical) has seen its Hong Kong stock exchange listing application lapse. The application, submitted on November 24, 2025, reached the end of its six-month validity period on May 24, 2026. At the time of submission, Morgan Stanley, BofA Securities, and CITIC Securities were acting as its joint sponsors.\nAccording to the prospectus, Mingyu Pharmaceutical, founded in 2018, is a biotechnology innovation company. The company operates with a dual growth strategy: a robust clinical-stage oncology portfolio built upon its proprietary antibody-drug conjugate (ADC) platform and a novel PD-1/VEGF bispecific antibody (bsAb), alongside its own late-stage immunology assets advancing towards commercialization.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}